Alliance EAY191-A6: A ComboMATCH Treatment Trial: FOLFOX in Combination with Binimetinib as 2nd Line Therapy for Patients with Advanced Biliary Tract Cancers with MAPK Pathway Alterations
| ClinicalTrials.gov Identifier |
| NCT05564403 |
| Institution Name |
| NCI |
| Institution Address (Street) |
| NCI - combomatch |
| Institution Phone |
| NA |
| Institution Website |
| https://www.allianceforclinicaltrialsinoncology.org/main/public/standard.xhtml?path=/Public/News-ComboMATCH-Aug2023 |
| Additional Institutions |
| All NCI sites are eligible to open the study |
| Principal Investigator |
| Ardaman Shergill |
| Principal Investigator Phone |
| 3124200978 |
| Principal Investigator Email |
| ashergill@bsd.uchicago.edu |
| Additional Principal Investigators |
| Chih-Yi Liao |
| Study Coordinator |
| Diane Feldman |
| Study Coordinator Phone |
| NA |
| Study Coordinator Email |
| dfeldman3@uchicagomedicine.org |
| Enrollment Information |
| ongoing |
| Study Start Date |
| 20230811 |
| Study End Date |
| 20250930 |
| Study Purpose |
| Test combination of targeted therapy in RAS mutated biliary tract cancers |
| Inclusion Criteria |
| - have had 1stline gemcitabine therapy - enroll on the master combo-match study |
| Exclusion Criteria |
| - must not have had 2nd line therapy - must not have had FOLFOX or MEKi previously |
| Required Tests Prior to Study |
| enrollment onto master combo match study baseline biopsy |
| Potential Side Effects |
| rash |
| Financial Assistance Available |
| No |